Blog
RSS FeedPosted by Michael Wonder on 04 May 2016
Call for patient input on a submission from Teva Pharmaceuticals for reslizumab
4 May 2016 - CADTH has received notice of a pending submission from Teva Pharmaceuticals for reslizumab for use by patients ...
Posted by Michael Wonder on 04 May 2016
PBS expenditure and prescriptions report 2014-15
4 May 2016 - The PBS expenditure and prescriptions report 2014-15 is now available. ...
Posted by Michael Wonder on 04 May 2016
Melanoma drug could be funded after boost in funding
4 May 2016 - A new generation melanoma drug is likely to be funded by PHARMAC after a $39 million boost ...
Posted by Michael Wonder on 04 May 2016
$124 million increase over four years for investment in new medicines
4 May 2016 - Medicines New Zealand is pleased that the New Zealand Government has today announced a $124 million increase ...
Posted by Michael Wonder on 04 May 2016
Proposals to list hepatitis C treatments
4 May 2016 - PHARMAC is seeking feedback on two proposals to list two new treatments for hepatitis C. ...
Posted by Michael Wonder on 04 May 2016
PHARMAC announces exciting opportunities for improved health from $39 million budget boost
4 May 2016 - PHARMAC is today opening consultations on seven new treatments across a wide range of health areas, says ...
Posted by Michael Wonder on 04 May 2016
Proposal to list nivolumab (Opdivo) for advanced melanoma
4 May 2016 - New Zealand has a very high incidence of advanced melanoma (metastatic or unresectable Stage III and IV ...
Posted by Michael Wonder on 02 May 2016
France gets G7 to discuss global regulation of medicine prices
2 May 2016 - France will press its G7 partners this month to launch an "irreversible" process to control the prices ...
Posted by Michael Wonder on 02 May 2016
Call for patient input on a submission from Raptor Pharmaceutical for Quinsair (levofloxacin hemihydrate)
2 May 2016 - CADTH has received notice of a pending submission from Raptor Pharmaceutical for Quinsair (levofloxacin hemihydrate) oral solution ...
Posted by Michael Wonder on 02 May 2016
Ibrutinib: indication of an additional clinical benefit in one of three therapeutic indications
2 May 2016 - The IQWIG in Germany has found ibrutinib has an additional clinical benefit for certain patients with ...
Posted by Michael Wonder on 02 May 2016
Umeclidinium for symptom relief in COPD: additional benefit is not proven
2 May 2016 - No sighificant differences for moderate disease and no data for severe disease. ...
Posted by Michael Wonder on 02 May 2016
Mepolizumab in severe asthma: additional benefit is not proven
2 May 2016 - Appropriate comparator therapy not implemented so the indirect comparison is unsuitable. ...
Posted by Michael Wonder on 02 May 2016
Cystic fibrosis patients campaign for drug Orkambi to be listed on Pharmaceutical Benefits Scheme
2 May 2016 - Without subsidy, it costs about US $260,000 each year. ...
Posted by Michael Wonder on 02 May 2016
Are the days of big pharma dominating the agenda of a PBAC meeting over?
2 May 2016 - The sponsor with the most number of submissions on the agenda for the next PBAC meeting ...
Posted by Michael Wonder on 02 May 2016
Post-market reviews of pulmonary arterial hypertension medicines and biological DMARDs to treat severe chronic plaque psoriasis
2 May 2016 - The public consultation process is now open for two PBAC post-market reviews. ...